+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Breast Cancer Therapeutics Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797979
The global breast cancer therapeutics market size was USD 30.2 billion in 2022, driven by the rising incidence of breast cancer across the globe. The market size is anticipated to grow at a CAGR of 10.8% during the forecast period of 2023-2031 to achieve a value of USD 75.8 billion by 2031.

Breast Cancer Therapeutics: Introduction

Breast cancer is a complex and devastating disease that affects millions of women worldwide. It is the most common cancer among women, with a significant impact on their health, well-being, and overall quality of life. The field of breast cancer therapeutics plays a crucial role in diagnosing, treating, and managing this disease.

The introduction of breast cancer therapeutics has revolutionized the way we approach the treatment of this condition. The development of various treatment modalities, including surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and immunotherapy, has provided healthcare professionals with a diverse arsenal of options to combat breast cancer.

The market for breast cancer therapeutics is driven by several factors. Firstly, the rising incidence of breast cancer, coupled with the growing awareness and early detection efforts, has led to an increased demand for effective treatment options. Secondly, advancements in medical research and technology have resulted in the discovery of new therapeutic targets and the development of more precise and targeted treatments. Thirdly, there is a continuous focus on improving patient outcomes, reducing treatment-related side effects, and enhancing the overall quality of life for breast cancer patients.

Key Trends in the Breast Cancer Therapeutics Market

Some key trends involved in the breast cancer therapeutics market are:
  • Targeted Therapies: There is a growing focus on targeted therapies in the field of breast cancer treatment. These therapies specifically target the molecular characteristics of a tumor, such as specific receptors or genetic mutations, to inhibit tumor growth and improve treatment outcomes. Targeted therapies have shown promising results in subtypes of breast cancer, such as HER2-positive and hormone receptor-positive breast cancer
  • Immunotherapy: Immunotherapy is emerging as a key trend in breast cancer treatment. It involves stimulating the body's immune system to recognize and attack cancer cells. Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, are being studied in clinical trials for their potential to enhance the immune response against breast cancer. Immunotherapy offers the potential for durable responses and long-term survival benefits
  • Personalized Medicine: The concept of personalized medicine is gaining traction in breast cancer treatment. With advances in genomic profiling, clinicians can identify specific genetic alterations in tumors and tailor treatment strategies accordingly. This approach aims to optimize treatment efficacy while minimizing unnecessary side effects. Personalized medicine also encompasses the use of biomarkers to predict treatment response and guide therapy selection

Breast Cancer Therapeutics Market Segmentations

Market Breakup by Therapy

Targeted Therapy

  • Abemaciclib
  • Ado-Trastuzumab Emtansine
  • Everolimus
  • Trastazumab
  • Ribociclib
  • Palbociclib
  • Pertuzumab
  • Olaparib

Hormonal Therapy

  • Selective Estrogen Receptor Modulators (SERMs)
  • Aromatase Inhibitors
  • Estrogen Receptor Downregulators (ERDs)

Chemotherapy

  • Taxanes
  • Anthracyclines
  • Anti-Metabolites
  • Alkylating Agents
  • Epothilones
  • Immunotherapy

Market Breakup by Cancer Type

  • Hormone Receptor
  • HER2+

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Route of Administration

  • Oral
  • Injectables

Market Breakup by End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Breast Cancer Therapeutics Market Scenario

Breast cancer therapeutics form a critical component of the healthcare industry, aiming to diagnose, treat, and manage one of the most prevalent forms of cancer affecting women worldwide. The market for breast cancer therapeutics is driven by the rising incidence of breast cancer, advancements in diagnostic techniques, and the continuous pursuit of more effective treatment options.

The global market for breast cancer therapeutics is characterized by a wide range of treatment modalities, including surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Each treatment modality plays a specific role in the management of breast cancer, with the choice depending on the stage, subtype, and individual patient characteristics.

Patient-centric care and personalized medicine are key trends in the breast cancer therapeutics market. Healthcare providers are increasingly focused on tailoring treatment strategies to individual patients, considering factors such as genetic profiles, tumour characteristics, and patient preferences. This personalized approach aims to optimize treatment outcomes and minimize potential side effects.

Furthermore, the market is witnessing an increased emphasis on supportive care and survivorship programs for breast cancer patients. This includes initiatives to manage treatment-related side effects, provide psychological support, and enhance the overall quality of life for survivors.

Breast Cancer Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Genentech, Inc.
  • Eli Lilly and Company
  • Novartis AG
  • AstraZeneca
  • Sanofi
  • Fresenius Kabi
  • Astellas Pharma Inc
  • Oncothyreon Inc
  • Genzyme Corporation
  • F. Hoffman-La Roche Pvt. Ltd
  • AbbVie, Inc
  • MacroGenics Inc
  • Onyx Pharmaceuticals, Inc
  • BioNumerik Pharmaceuticals Inc
  • Celldex Therapeutics.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Breast Cancer Therapeutics Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Breast Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Breast Cancer Epidemiology (2016-2031)
5.3 Europe Breast Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Breast Cancer Epidemiology (2016-2031)
5.5 Latin America Breast Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Breast Cancer Epidemiology (2016-2031)
6 Global Breast Cancer Therapeutics Market Overview
6.1 Global Breast Cancer Therapeutics Market Historical Value (2016-2022)
6.2 Global Breast Cancer Therapeutics Market Forecast Value (2023-2031)
7 Global Breast Cancer Therapeutics Market Landscape
7.1 Breast Cancer Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Breast Cancer Therapeutics: Product Landscape
7.2.1 Analysis by Therapy
7.2.2 Analysis by Cancer Type
7.2.3 Analysis by Distribution Channel
7.2.4 Analysis by Route of Administration
7.2.5 Analysis by End User
8 Breast Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Breast Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Breast Cancer Therapeutics Market Segmentation
11.1 Global Breast Cancer Therapeutic Market by Therapy
11.1.1 Market Overview
11.1.2 Targeted Therapy
11.1.2.1 Abemaciclib
11.1.2.2 Ado-Trastuzumab Emtansine
11.1.2.3 Everolimus
11.1.2.4 Trastazumab
11.1.2.5 Ribociclib
11.1.2.6 Palbociclib
11.1.2.7 Pertuzumab
11.1.2.8 Olaparib
11.1.3 Hormonal Therapy
11.1.3.1 Selective Estrogen Receptor Modulators (SERMs)
11.1.3.2 Aromatase Inhibitors
11.1.3.3 Estrogen Receptor Downregulators (ERDs)
11.1.4 Chemotherapy
11.1.4.1 Taxanes
11.1.4.2 Anthracyclines
11.1.4.3 Anti-Metabolites
11.1.4.4 Alkylating Agents
11.1.4.5 Epothilones
11.1.5 Immunotherapy
11.2 Global Breast Cancer Therapeutic Market by Cancer Type
11.2.1 Market Overview
11.2.2 Hormone Receptor
11.2.3 HER2+
11.3 Global Breast Cancer Therapeutic Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Online Pharmacies
11.3.5 Others
11.4 Global Breast Cancer Therapeutic Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Injectables
11.5 Global Breast Cancer Therapeutic Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Homecare
11.5.4 Specialty Clinics
11.5.5 Others
11.6 Global Breast Cancer Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Breast Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Breast Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Breast Cancer Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Breast Cancer Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Breast Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Genentech, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Eli Lilly and Company
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 AstraZeneca
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Sanofi
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Fresenius Kabi
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Astellas Pharma Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Oncothyreon Inc
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Genzyme Corporation
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 F. Hoffman-La Roche Pvt. Ltd
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 AbbVie, Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 MacroGenics Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Onyx Pharmaceuticals, Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 BioNumerik Pharmaceuticals Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Celldex Therapeutics.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
24 Breast Cancer Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Genentech, Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Astrazeneca
  • Sanofi
  • Fresenius Kabi
  • Astellas Pharma Inc.
  • Oncothyreon Inc
  • Genzyme Corporation
  • F. Hoffman-La Roche Pvt. Ltd
  • Abbvie, Inc.
  • Macrogenics Inc.
  • Onyx Pharmaceuticals, Inc.
  • Bionumerik Pharmaceuticals Inc.
  • Celldex Therapeutics.

Methodology

Loading
LOADING...

Table Information